Cancer diagnosis & prognosis最新文献

{"title":"The Potential of the C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index as a Prognostic Biomarker in Colorectal Cancer.","authors":"Shunsuke Furukawa, Masatsugu Hiraki, Naoya Kimura, Naohiko Kohya, Masashi Sakai, Akashi Ikubo, Ryuichiro Samejima","doi":"10.21873/cdp.10449","DOIUrl":"https://doi.org/10.21873/cdp.10449","url":null,"abstract":"<p><strong>Background/aim: </strong>The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index is an innovative immunonutritional biomarker calculated from CRP, serum albumin, and lymphocyte count levels. This study aimed to determine the significance of the preoperative CALLY index as a prognostic biomarker in patients with stage II-III colorectal cancer who underwent colorectal surgery.</p><p><strong>Patients and methods: </strong>This retrospective study included 223 patients who underwent colorectal surgery for stage II-III colorectal cancer. The CALLY index was calculated as follows: (albumin × lymphocyte)/(CRP × 104). The patients were divided into CALLY-high group (n=112) and CALLY-low group (n=111) according to the preoperative CALLY index. The associations between the preoperative CALLY index and recurrence-free survival (RFS) and overall survival (OS) were evaluated.</p><p><strong>Results: </strong>The cutoff value of the CALLY index was 3.41. The Kaplan-Meier survival curves for both RFS and OS in patients with stage II-III colorectal cancer demonstrated worse outcomes in the CALLY-low group than in the CALLY-high group (p=0.062 and p=0.008, respectively). A subgroup analysis of both stage II and stage III showed that patients in the CALLY-low group who did not receive postoperative adjuvant chemotherapy had the worst RFS and OS.</p><p><strong>Conclusion: </strong>The preoperative CALLY index may serve as a prognostic biomarker in patients with colorectal cancer. Additionally, a low CALLY index may indicate a poorer prognosis, particularly in patients who did not receive postoperative adjuvant chemotherapy.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 3","pages":"370-377"},"PeriodicalIF":0.0,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced Metastatic Malignant Triton Tumor in Neurofibromatosis Type 1: A Case Report and Management Challenges.","authors":"Kazuhiko Hashimoto, Shunji Nishimura, Koji Goto","doi":"10.21873/cdp.10454","DOIUrl":"https://doi.org/10.21873/cdp.10454","url":null,"abstract":"<p><strong>Background/aim: </strong>A malignant Triton tumor (MTT) is a rare and aggressive soft tissue sarcoma associated with poor prognosis and with no established treatment protocol.</p><p><strong>Case report: </strong>A 38-year-old man presented with severe right thigh pain and limited hip motion. Since childhood, the patient had a mass on their thigh, accompanied by café-au-lait spots. Upon admission, a biopsy confirmed MTT that had metastasized to the lungs. Preoperative radiation therapy was administered to reduce the tumor size; however, the tumor did not shrink. Extensive resection was not feasible because of the tumor size and location, prompting a decision to perform volume reduction surgery aimed at alleviating the patient's pain and improving mobility. Although the surgery provided temporary relief from the symptoms, the patient died two weeks later.</p><p><strong>Conclusion: </strong>MTT requires a multidisciplinary approach that includes surgery, chemotherapy, and radiation therapy; however, in advanced cases such as this one, palliative measures may be more appropriate. This case underscores the challenges in managing MTT and highlights the potential role of volume reduction surgery in improving the quality of life of patients with significant symptoms. Despite the poor prognosis, symptom palliation during the two weeks leading up to the patient's death was significant, illustrating the importance of addressing pain and mobility issues while considering overall treatment strategies in such complex cases. These findings emphasize the need for further research on effective management options for MTT to improve patient outcomes.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 3","pages":"410-416"},"PeriodicalIF":0.0,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Early Progression in Advanced Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab.","authors":"Sosuke Yamamoto, Toru Aoyama, Yukio Maezawa, Itaru Hashimoto, Ryuki Esashi, Keisuke Kazama, Mamoru Uchiyama, Koji Numata, Mihwa Hu, Momoko Fukuda, Kiyoko Shimada, Ayako Tamagawa, Aya Saito, Yukawa Norio","doi":"10.21873/cdp.10447","DOIUrl":"https://doi.org/10.21873/cdp.10447","url":null,"abstract":"<p><strong>Background/aim: </strong>Lymphocyte-to-C-reactive protein ratio (LCR) is a useful biomarker for predicting the prognosis of various cancers. This study examined the effect of LCR on the oncological prognosis of patients with gastric cancer who underwent curative resection at our institution and considered the mechanisms involved.</p><p><strong>Patients and methods: </strong>In this retrospective cohort study, 258 subjects were selected from the medical records of patients who underwent curative resection for gastric cancer at Yokohama City University between 2005 and 2020. The LCR was calculated using the following formula: LCR=lymphocyte count (number/μl)/C-reactive protein (mg/dl).</p><p><strong>Results: </strong>The cutoff value for LCR was set at 9,000, and 258 patients were classified into the LCR-low (<9,000) (58 patients) and LCR-high (>9,000) (200 patients) groups. The overall survival (OS) and recurrence-free survival (RFS) rates of the two groups were compared. The 5-year overall survival rate was 54.2% in the LCR-low group and 75.2% in the LCR-high group (p<0.001), and a multivariate analysis showed that it was a useful prognostic factor [hazard ratio (HR)=1.744, 95% confidence interval (CI)=1.009-3.014, p=0.046]. In addition, with regard to RFS, there was a significant difference in the 5-year RFS between the LCR-low group (50.4%) and the LCR-high group (72.3%) (p<0.001). Regarding the comparison of the postoperative clinical course between the two groups, the peritoneal recurrence rate was 24.1% in the LCR-low group and 7.5% in the LCR-high group (p<0.001).</p><p><strong>Conclusion: </strong>Preoperative LCR is a useful prognostic factor for predicting the oncological prognosis of patients with gastric cancer undergoing curative resection. Thus, the LCR may be a useful tool for the treatment and perioperative management of patients with gastric cancer.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 3","pages":"353-362"},"PeriodicalIF":0.0,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144053462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Pneumocystis</i> Pneumonia in a Patient With Colorectal Cancer Receiving Bevacizumab and mFOLFOX6 Therapy.","authors":"Masatoshi Maki, Ryo Takada, Naoyuki Nomura, Yuki Chiko, Satoru Senoo, Yoko Takahashi, Seiji Saito, Terutaka Hamaoka","doi":"10.21873/cdp.10452","DOIUrl":"https://doi.org/10.21873/cdp.10452","url":null,"abstract":"<p><strong>Background/aim: </strong>Pneumocystis pneumonia (PCP) can be a life-threatening fungal infection for immunocompromised individuals. We report a case of PCP in a 75-year-old male with colorectal cancer receiving bevacizumab plus mFOLFOX6 (oxaliplatin, leucovorin, and 5-fluorouracil) therapy.</p><p><strong>Case report: </strong>The patient, diagnosed with unresectable advanced colorectal cancer, developed fever and neutropenia during the 40th course of bevacizumab plus mFOLFOX6 therapy and was diagnosed with febrile neutropenia. Moreover, laboratory tests and imaging studies indicated PCP. Although initial treatment with corticosteroids and trimethoprim-sulfamethoxazole temporarily improved the patient's condition, the patient later developed acute respiratory distress syndrome and succumbed to the disease. Lymphocytopenia associated with the prolonged bevacizumab plus mFOLFOX6 therapy may have contributed to the onset of PCP.</p><p><strong>Conclusion: </strong>This case reaffirms that advanced age, immunosuppression, and cumulative steroid exposure are critical risk factors for PCP. Early imaging and prophylactic TMP-SMX administration should be considered in high-risk patients. Early intervention is crucial to prevent PCP progression to ARDS in patients with solid tumors.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 3","pages":"396-403"},"PeriodicalIF":0.0,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicenter Retrospective Analysis of Pulmonary Sarcomatoid Carcinoma Clinically Diagnosed Using Small Biopsy Specimens.","authors":"Minehiko Inomata, Takeshi Tsuda, Tomomi Ichikawa, Masahiro Matsumoto, Isami Mizushima, Kenji Azechi, Naoki Takata, Nozomu Murayama, Zenta Seto, Kotaro Tokui, Yasuaki Masaki, Seisuke Okazawa, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Hirokazu Taniguchi","doi":"10.21873/cdp.10448","DOIUrl":"https://doi.org/10.21873/cdp.10448","url":null,"abstract":"<p><strong>Background/aim: </strong>Pulmonary sarcomatoid carcinoma is a rare disease known for its aggressiveness, with numerous studies evaluating the efficacy of various therapeutic approaches. However, pulmonary sarcomatoid carcinoma is histologically defined according to WHO classification based on surgical specimens, whereas in clinical practice, most cases of advanced lung cancer are diagnosed based on small biopsy specimens. This retrospective study aimed to present the clinical course of patients diagnosed with pulmonary sarcomatoid carcinoma based on small biopsy specimens.</p><p><strong>Patients and methods: </strong>Data of patients who were diagnosed with pulmonary sarcomatoid carcinoma based on small biopsy specimens and treated with platinum-doublet chemotherapy and/or an immune checkpoint inhibitor-containing regimen between 2005 and 2022 were analyzed.</p><p><strong>Results: </strong>Data from 12 patients were analyzed, including five patients treated with platinum-doublet chemotherapy and 11 patients treated with an immune checkpoint inhibitor-containing regimen. The median progression-free survival among the five patients treated with platinum-doublet chemotherapy was 1.5 months [95% confidence interval (CI)=0.7-4.1]. Of these, four patients subsequently received immune checkpoint inhibitor-containing therapy. The median overall survival from the initiation of platinum-doublet chemotherapy in these five patients was 14.7 months (95%CI=1.2-16.2). In contrast, 11 patients treated with immune checkpoint inhibitor therapy showed a median progression-free survival and overall survival of 8.9 months [95%CI=0.3-not estimated (NE)] and 10.8 months (95%CI=1.0-NE), respectively.</p><p><strong>Conclusion: </strong>Pulmonary sarcomatoid carcinoma diagnosed based on small biopsy specimens is refractory to platinum-doublet chemotherapy, and immune checkpoint inhibitor therapy may improve the prognosis.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 3","pages":"363-369"},"PeriodicalIF":0.0,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144029235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative Predictive Factors for Seminal Vesicle Invasion (pT3b) in Robotic-assisted Radical Prostatectomy.","authors":"Kazuhiko Oshinomi, Shota Kikuchi, Hirotaka Kishi, Anju Hayashi, Sho Okada, Masahiro Kurokawa, Toshiki Mugita, Tatsuki Inoue, Motoki Yamagishi, Yoshihiro Nakagami, Masakazu Nagata, Takashi Fukagai","doi":"10.21873/cdp.10443","DOIUrl":"https://doi.org/10.21873/cdp.10443","url":null,"abstract":"<p><strong>Background/aim: </strong>Robot-assisted radical prostatectomy (RARP) outcomes improve with surgical experience, but preoperative prediction of disease stage is crucial to avoid unexpected T stage upgrades, such as pT3b. This study aimed to identify preoperative predictive factors for pT3b (seminal vesicle invasion) following RARP.</p><p><strong>Patients and methods: </strong>Out of 299 RARP performed between 2013 and 2020, 246 cases without preoperative hormone therapy were included. Of these, 19 cases (7.7%) were pT3b. T classification was performed using magnetic resonance imaging (MRI), and 12-site prostate biopsies were conducted. Cox proportional hazards, logistic regression analysis, and Kaplan-Meier analyses were used.</p><p><strong>Results: </strong>The 3-year prostate specific antigen (PSA) recurrence-free survival rate was 87% but significantly lower at 70% for pT3b cases. Multivariate logistic regression analysis identified the International Society of Urological Pathology (ISUP) grade group at biopsy as the only significant preoperative predictor of pT3b.</p><p><strong>Conclusion: </strong>pT3b is associated with increased postoperative biochemical recurrence risk, and ISUP grade group at biopsy serves as a significant preoperative predictive factor for pT3b.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 3","pages":"313-318"},"PeriodicalIF":0.0,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046658/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship Between T790M Allele Frequency and Therapeutic Effects Before and After EGFR-TKI Administration Using Droplet Digital PCR in Non-small-cell Lung Cancer With EGFR Mutation.","authors":"Koichi Ogawa, Hiroyasu Kaneda, Yasuhiro Koh, Yoshiya Matsumoto, Kenji Sawa, Motohiro Tamiya, Nobuhisa Ishikawa, Kenichi Minami, Hidekazu Suzuki, Yosuke Eguchi, Masaki Kanazu, Yuki Sato, Tomoya Kawaguchi","doi":"10.21873/cdp.10441","DOIUrl":"https://doi.org/10.21873/cdp.10441","url":null,"abstract":"<p><strong>Background/aim: </strong>This study aimed to investigate the effectiveness of sequential treatment with afatinib and osimertinib by clarifying the correlation between therapeutic effects and <i>EGFR</i> T790M mutant allele frequency.</p><p><strong>Patients and methods: </strong>From August 2013 to July 2019, tumor samples from before and after epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) administration were collected from patients from eight institutions. We measured T790M mutant allele frequency using droplet digital polymerase chain reaction using biopsy specimens from patients mainly treated with afatinib and analyzed the T790M to EGFR-activating mutation ratio (T/A ratio) in pre- and post-biopsy tissue.</p><p><strong>Results: </strong>Among 36 patients (afatinib group: n=24, first-generation EGFR-TKI group: n=12) with preserved pre- and post-biopsy tissue, the median T/A ratios before (pre-T/A ratio) and after EGFR-TKI administration (post-T/A ratio) in the afatinib group were 0.005 and 0.014, and those in the first-generation EGFR-TKI group were 0.026 and 0.352, respectively. The results of a Mann-Whitney <i>U</i>-test revealed that the difference between the pre-T/A and post-T/A ratios was not higher in the afatinib group than in the first-generation EGFR-TKI (<i>p</i>=0.0372). No significant difference in progression-free or overall survival was found between the two groups.</p><p><strong>Conclusion: </strong>Compared with first-generation EGFR-TKI treatment, treatment with afatinib did not affect changes in the T/A ratio.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 3","pages":"285-299"},"PeriodicalIF":0.0,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Infraorbital B-cell Lymphoma Masquerading as an Abscess.","authors":"Saad Rashid, Mudassar Sandozi, Saagar Pamulapati, Ajay Doniparthi, Suneha Pocha, Mohammed Ahmed Khan","doi":"10.21873/cdp.10437","DOIUrl":"10.21873/cdp.10437","url":null,"abstract":"<p><strong>Background/aim: </strong>Primary ocular adnexal lymphomas pose a diagnostic challenge for physicians due to their nonspecific symptom presentation and resemblance to other periorbital masses, such as skin and soft tissue infections. Early diagnosis and appropriate management are crucial for optimizing outcomes and coordination of therapy.</p><p><strong>Case report: </strong>We present a case of a 67-year-old male with a history of infraorbital trauma, initially managed as a soft tissue infection, which was later revealed to be a large B-cell lymphoma. Despite multiple specialty evaluations, including dermatology, ophthalmology, plastic surgery, and ENT, among others, diagnosis was delayed, leading to worsening symptoms and vision impairment.</p><p><strong>Conclusion: </strong>This case highlights the importance of considering ocular adnexal lymphomas in the differential diagnosis of periorbital masses and the need for interdisciplinary collaboration for timely recognition and treatment.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 2","pages":"255-260"},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871858/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Factors for the Efficacy of Head and Neck Photoimmunotherapy and Optimization of Treatment Schedules.","authors":"Daisuke Nishikawa, Takuya Shimabukuro, Hidenori Suzuki, Shintaro Beppu, Hoshino Terada, Yoshiaki Kobayashi, Nobuhiro Hanai","doi":"10.21873/cdp.10428","DOIUrl":"10.21873/cdp.10428","url":null,"abstract":"<p><strong>Background/aim: </strong>Head and neck photoimmunotherapy (HN-PIT) is a promising treatment for unresectable locally advanced or recurrent head and neck cancers. However, the optimal tumor characteristics and treatment schedules remain unclear. This study aimed to identify factors associated with treatment efficacy and assess the effectiveness of treatment schedules.</p><p><strong>Patients and methods: </strong>A retrospective cohort study of patients treated with HN-PIT at Aichi Cancer Center Hospital from January 2021 to October 2024 was conducted. Tumor characteristics, treatment cycles, and outcomes were analyzed. The thickness and longest diameter of the tumors were evaluated, and treatment intervals were assessed for their association with complete response (CR).</p><p><strong>Results: </strong>Among the 19 patients (30 cycles), CR was observed exclusively in local lesions. Smaller and thinner lesions showed significantly better treatment responses. Thinner lesions were more likely to achieve CR after a single cycle, whereas intermediate-thickness tumors often required multiple cycles with shorter intervals. The regional lesions did not achieve CR, even with multiple cycles and shorter intervals. Age was a significant factor influencing CR.</p><p><strong>Conclusion: </strong>HN-PIT demonstrated promising efficacy for local lesions, particularly for smaller and thinner lesions. Optimizing treatment schedules, including shorter intervals for intermediate lesions, is critical for improving outcomes. Further research is needed to enhance the efficacy for regional lesions and refine treatment schedules.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 2","pages":"179-188"},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871859/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative Visitation Effect on Quality of Life of Patients Undergoing Transarterial Chemoembolization for Hepatocellular Carcinoma.","authors":"Toru Ishikawa, Atsuko Suzuki, Hiromi Yamamoto, Narumi Arita, Yusuke Matsuhashi, Nao Kobayashi, Eriko Nakagawa, Nanako Terai, Asami Hoshii, Terasu Honma","doi":"10.21873/cdp.10434","DOIUrl":"10.21873/cdp.10434","url":null,"abstract":"<p><strong>Background/aim: </strong>While transcatheter arterial chemoembolization (TACE) is a treatment option for patients with Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma, it is associated with physical and psychological pain, with concerns regarding its effect on quality of life (QOL). In December 2020, we introduced radiology nurse-led preoperative visits to patients undergoing TACE. This study aimed to examine QOL improvement following a preoperative visit.</p><p><strong>Patients and methods: </strong>Among patients scheduled to undergo TACE for hepatocellular carcinoma, 48 received a preoperative visit and 22 did not (control group). We compared QOL variables between the groups using the Short-Form 36 (SF-36) at hospital admission and discharge.</p><p><strong>Results: </strong>No significant between-group differences in clinical backgrounds were observed. In the control group, SF-36 scores at admission/discharge were as follows: physical function (PF), 42.87±14.46/34.71±19.70 and mental health (MH), 51.32±8.67/45.26±11.35, respectively. In the subgroup analysis, the PF/MH item results were PF 40.89±14.55/31.46±19.25 and MH 51.10±9.07/44.79±12.04 for older adult patients in the control group. In the preoperative visit group, PF (admission, 42.31±14.23; discharge, 41.54±14.12; <i>p</i>=0.989) and MH (admission, 48.45±10.97; discharge, 49.59±10.05; <i>p</i>=0.399) were maintained.</p><p><strong>Conclusion: </strong>PF/MH items at admission and discharge were maintained or improved in the preoperative visit group, whereas those in the control group showed a significant decrease. Preoperative visits contributed to maintaining patient QOL.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 2","pages":"230-237"},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}